Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications

Hu, Robert W.; Carey, Elizabeth J.; Lindor, Keith D.; Tabibian, James H.

doi:10.5604/01.3001.0010.5273

Cited by 40 publications

(17 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 Other pharmacotherapies currently under investigation for PSC, including but not limited to obeticholic acid, have been recently reviewed elsewhere. 165,166 …”

Section: Treatment Of Pscmentioning

confidence: 99%

Primary sclerosing cholangitis: A review and update

Tabibian

Bowlus

2017

Liver Research

Self Cite

View full text Add to dashboard Cite

Primary sclerosing cholangitis (PSC) is a rare, chronic, cholestatic liver disease of uncertain etiology characterized biochemically by cholestasis and histologically and cholangiographically by fibro-obliterative inflammation of the bile ducts. In a clinically significant proportion of patients, PSC progresses to cirrhosis, end-stage liver disease, and/or hepatobiliary cancer, though the disease course can be highly variable. Despite clinical trials of numerous pharmacotherapies over several decades, safe and effective medical therapy remains to be established. Liver transplantation is an option for select patients with severe complications of PSC, and its outcomes are generally favorable. Periodic surveillance testing for pre- as well as post-transplant patients is a cornerstone of preventive care and health maintenance. Here we provide an overview of PSC including its epidemiology, etiopathogenesis, clinical features, associated disorders, surveillance, and emerging potential therapies.

show abstract

“…44 Other pharmacotherapies currently under investigation for PSC, including but not limited to obeticholic acid, have been recently reviewed elsewhere. 165,166 …”

Section: Treatment Of Pscmentioning

confidence: 99%

Primary sclerosing cholangitis: A review and update

Tabibian

Bowlus

2017

Liver Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…for 8 weeks led to a significant reduction in transaminase levels, waist circumference, body mass index, but especially the degree of hepatic steatosis in 75% of the treated subjects. Although these data are particularly promising, it should be noted that the positive effects are often observed for high supplementations (usually >1500 mg/day) of pure curcumin, with consequent problems of treatment compliance and costs (partially mitigated with the use of new, more bioavailable pharmaceutical formulations) [ 72 ]. This is because curcumin also has a poor oral bioavailability, that can, however, be improved by “ad hoc” pharmaceutical techniques.…”

Section: Resultsmentioning

confidence: 99%

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

2018

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a clinical condition characterized by lipid infiltration of the liver, highly prevalent in the general population affecting 25% of adults, with a doubled prevalence in diabetic and obese patients. Almost 1/3 of NAFLD evolves in Non-Alcoholic SteatoHepatitis (NASH), and this can lead to fibrosis and cirrhosis of the liver. However, the main causes of mortality of patients with NAFLD are cardiovascular diseases. At present, there are no specific drugs approved on the market for the treatment of NAFLD, and the treatment is essentially based on optimization of lifestyle. However, some nutraceuticals could contribute to the improvement of lipid infiltration of the liver and of the related anthropometric, haemodynamic, and/or biochemical parameters. The aim of this paper is to review the available clinical data on the effect of nutraceuticals on NAFLD and NAFLD-related parameters. Relatively few nutraceutical molecules have been adequately studied for their effects on NAFLD. Among these, we have analysed in detail the effects of silymarin, vitamin E, vitamin D, polyunsaturated fatty acids of the omega-3 series, astaxanthin, coenzyme Q10, berberine, curcumin, resveratrol, extracts of Salvia milthiorriza, and probiotics. In conclusion, Silymarin, vitamin E and vitamin D, polyunsaturated fatty acids of the omega-3 series, coenzyme Q10, berberine and curcumin, if well dosed and administered for medium–long periods, and associated to lifestyle changes, could exert positive effects on NAFLD and NAFLD-related parameters.

show abstract

“…Currently, there are few reports on drug treatments for CCA. Studies suggest that 14-deoxy-11, 12-didehydroandrographolide and curcumin may be the potential drugs for the treatment of CCA ( 10 , 11 ). Even with the large number of tested drugs, the results remain unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma

et al. 2018

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is one of the most common epithelial cell malignancies worldwide. However, its prognosis is poor. The aim of the present study was to examine the prognostic landscape and potential therapeutic targets for CCA. RNA sequencing data and clinical information were downloaded from The Cancer Genome Atlas (TCGA) dataset and processed. A total of 172 genes that were significantly associated with overall survival of patients with CCA were identified using the univariate Cox regression method. Bioinformatics tools were applied using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and gene ontology (GO). It was identified that ‘Wnt signaling pathway’, ‘cytoplasm’ and ‘AT DNA binding’ were the three most significant GO categories of CCA survival-associated genes. ‘Transcriptional misregulation in cancer’ was the most significant pathway identified in the KEGG analysis. Using the Drug-Gene Interaction database, a drug-gene interaction network was constructed, and 31 identified genes were involved in it. The most meaningful potential therapeutic targets were selected via protein-protein and gene-drug interactions. Among these genes, polo-like kinase 1 (PLK1) was identified to be a potential target due to its significant upregulation in CCA. To rapidly find molecules that may affect these genes, the Connectivity Map was queried. A series of molecules were selected for their potential anti-CCA functions. 0297417-0002B and tribenoside exhibited the highest connection scores with PLK1 via molecular docking. These findings may offer novel insights into treatment and perspectives on the future innovative treatment of CCA.

show abstract

Curcumin in Hepatobiliary Disease: Pharmacotherapeutic Properties and Emerging Potential Clinical Applications

Cited by 40 publications

References 65 publications

Primary sclerosing cholangitis: A review and update

Primary sclerosing cholangitis: A review and update

Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence

Survival analysis of genome-wide profiles coupled with Connectivity Map database mining to identify potential therapeutic targets for cholangiocarcinoma

Contact Info

Product

Resources

About